Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
J Thromb Haemost ; 7(11): 1915-9, 2009 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-19691482

RESUMEN

BACKGROUND: Interaction of P-selectin with its glycoprotein ligand (P-selectin glycoprotein ligand type 1) mediates inflammatory processes that may also include vascular thrombosis. Platelet P-selectin expression is increased in patients with coronary heart disease, and its antagonism represents a potential future therapeutic target for the prevention and treatment of atherothrombosis. AIM: To investigate the effects of the novel small molecule P-selectin antagonist PSI-697 on thrombus formation in humans. METHODS AND RESULTS: In a double-blind randomized crossover study, thrombus formation was measured in 12 healthy volunteers, using the Badimon ex vivo perfusion chamber under conditions of low and high shear stress. Saline placebo, low-dose (2 m) and high-dose (20 m) PSI-697 and the glycoprotein IIb-IIIa receptor antagonist tirofiban (50 ng mL(-1)) were administered into the extracorporeal circuit prior to the perfusion chamber. As compared with saline placebo, blockade of platelet glycoprotein IIb-IIIa receptor with tirofiban produced 28% and 56% reductions in thrombus formation in the low-shear and high-shear chambers, respectively. PSI-697 caused a dose-dependent, but more modest, reduction in thrombus formation. Low-dose PSI-796 (2 m) reduced total thrombus area by 14% (P = 0.04) and 30% (P = 0.0002) in the low-shear and high-shear chambers, respectively. At the high dose (20 m), PSI-697 reduced total thrombus area by 18% (P = 0.0094) and 41% (P = 0.0008) in the low-shear and high-shear chambers, respectively. CONCLUSIONS: P-selectin antagonism with PSI-697 reduces ex vivo thrombus formation in humans. These findings provide further evidence that P-selectin antagonism may be a potential target for the prevention and treatment of cardiovascular disease.


Asunto(s)
Selectina-P/antagonistas & inhibidores , Trombosis/prevención & control , Adolescente , Adulto , Sangre/efectos de los fármacos , Células Cultivadas , Estudios Cruzados , Método Doble Ciego , Humanos , Hidroxiquinolinas/farmacología , Perfusión , Complejo GPIIb-IIIa de Glicoproteína Plaquetaria/antagonistas & inhibidores , Trombosis/tratamiento farmacológico , Tirofibán , Tirosina/análogos & derivados , Tirosina/farmacología , Adulto Joven
2.
Thromb Haemost ; 82(5): 1443-5, 1999 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-10595635

RESUMEN

An inhibitory anti-factor IX/IXa antibody (BC2) has been investigated as an anti-thrombotic agent in a rat venous thrombosis model. The treatment of rats post-injury with a single bolus dose of BC2 (3 mg/kg, i.v.) resulted in an approximately 4 fold reduction in venous thrombus mass (P = 0.043). This efficacy was matched by a minimal (<2.5 fold) prolongation of the aPTT and had no effect on the prothrombin time (PT). Heparin by comparison, given as a bolus followed by continuous infusion, at doses comparable in efficacy at reducing thrombus formation, prolonged the aPTT >50 fold. These results demonstrate that the anti-factor IX/IXa antibody (BC2), when compared to heparin, can effectively reduce venous thrombosis with less disruptive consequences on blood clotting.


Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Factor IX/antagonistas & inhibidores , Vena Cava Inferior , Trombosis de la Vena/prevención & control , Animales , Anticuerpos Monoclonales/administración & dosificación , Anticuerpos Monoclonales/inmunología , Especificidad de Anticuerpos , Evaluación Preclínica de Medicamentos , Epítopos/inmunología , Factor IX/inmunología , Factor IX/fisiología , Factor IXa/inmunología , Heparina/administración & dosificación , Heparina/uso terapéutico , Infusiones Intravenosas , Inyecciones Intravenosas , Masculino , Ratones , Tiempo de Tromboplastina Parcial , Estructura Terciaria de Proteína , Tiempo de Protrombina , Ratas , Ratas Sprague-Dawley
3.
Pharmacology ; 54(1): 24-32, 1997 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-9065958

RESUMEN

The effects of carvedilol, a vasodilating beta-blocker with antioxidant activity, and nifedipine, a calcium channel blocker, were investigated on aortic lipid deposition and the accumulation of monocytes and foam cells at the sites of atherosclerotic lesions in rats subjected to a hypercholesterolemic diet. Fifty rats were randomly assigned to the following experimental groups: (1) regular rat chow (n = 5); (2) regular rat chow supplemented with a high-cholesterol diet (1% cholesterol and 1% cholic acid; n = 15); (3) a high-cholesterol diet plus nifedipine (n = 15), and (4) a high-cholesterol diet plus carvedilol (n = 15). Animals were maintained on these diets for 12 weeks. None of the treatment groups had blood pressures that were outside the normotensive range, and no significant differences in plasma lipid levels were observed among the high-cholesterol diet and drug-treated groups. There was a significantly lower lipid content (p < 0.001) in the thoracic aortas of the nifedipine-treated (211 +/- 23 nmol/mm2) and carvedilol-treated (182 +/- 23 nmol/mm2) groups compared to cholesterol-fed controls (242 +/- 27 nmol/mm2). Furthermore, carvedilol-treated animals showed significantly less (p < 0.001) lipid accumulation than did the nifedipine-treated animals. The number of monocytes and foam cells were decreased in both drug-treated groups compared to animals receiving high-cholesterol diets without drug treatment. The results demonstrate that treatment with carvedilol or nifedipine can significantly inhibit lipid deposition in the aorta and reduce monocyte and foam cell accumulation, and that carvedilol is significantly more effective than nifedipine in inhibiting lipid deposition.


Asunto(s)
Antagonistas Adrenérgicos beta/uso terapéutico , Arteriosclerosis/prevención & control , Carbazoles/uso terapéutico , Hipercolesterolemia/tratamiento farmacológico , Metabolismo de los Lípidos , Propanolaminas/uso terapéutico , Vasodilatadores/uso terapéutico , Animales , Aorta Torácica/metabolismo , Aorta Torácica/patología , Arteriosclerosis/etiología , Arteriosclerosis/fisiopatología , Bloqueadores de los Canales de Calcio/uso terapéutico , Carvedilol , Hipercolesterolemia/complicaciones , Masculino , Nifedipino/uso terapéutico , Ratas , Ratas Wistar
4.
Eur J Pharmacol ; 180(1): 1-12, 1990 May 03.
Artículo en Inglés | MEDLINE | ID: mdl-2163861

RESUMEN

Norvaline2-thyrotropin-releasing hormone ([Nva2]TRH) has been described as a thyrotropin-releasing hormone (TRH) analog with no thyrotropin (TSH)-releasing capacity but enhanced analeptic activity compared with TRH, as shown by the reversal of haloperidol-induced catalepsy. We have evaluated the receptor-binding properties of [Nva2]TRH in homogenates of rat anterior pituitary, hypothalamus, brainstem and cortex tissue, using [3H]TRH and [3H][3-Me-His2]TRH as radioligands. Apparent Ki values at high affinity TRH-binding sites, labelled predominantly by [3H][3-Me-His2]TRH, ranged from 17.0 to 36.9 microM in all tested regions. Additionally, [Nva2]TRH was shown to compete with [3H]TRH at low affinity TRH-binding sites with similar affinities. It is concluded that the loss of TSH-releasing activity of [Nva2]TRH appears to be due to a drastic reduction in binding affinity to the high affinity TRH receptor subtype. Its analeptic activity, however, may be mediated by low affinity TRH binding sites which are predominantly labelled by [3H]TRH or by yet unidentified mechanisms.


Asunto(s)
Encéfalo/metabolismo , Receptores de Neurotransmisores/metabolismo , Hormona Liberadora de Tirotropina/análogos & derivados , Animales , Unión Competitiva/efectos de los fármacos , Encéfalo/efectos de los fármacos , Tronco Encefálico/efectos de los fármacos , Tronco Encefálico/metabolismo , Corteza Cerebral/efectos de los fármacos , Corteza Cerebral/metabolismo , Filtración , Hipotálamo/efectos de los fármacos , Hipotálamo/metabolismo , Técnicas In Vitro , Cinética , Masculino , Ácido Pirrolidona Carboxílico/análogos & derivados , Ratas , Ratas Endogámicas , Receptores de Hormona Liberadora de Tirotropina , Hormona Liberadora de Tirotropina/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA